The impact of inpatient rivaroxaban versus warfarin on hospital-based outcomes when used for stroke prevention in patients with anticoagulant naïve, new-onset nonvalvular atrial fibrillation

Target specific oral anticoagulants (TSOACs) are alternatives to warfarin for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Stroke prophylaxis in NVAF does not require immediate therapeutic anticoagulation; however, delaying discharge in patients treated with warfarin to achieve a therapeutic international normalized ratio (INR) may prolong hospital length of stay (LOS) compared to use of a TSOAC. We aimed to evaluate patients hospitalized for new-onset, NVAF that were initiated on either rivaroxaban or warfarin for stroke prevention on hospital-based outcomes.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Letter to the Editor Source Type: research